GW

GW Vitek CO.,LTD.

Develops research antibodies and distributes scientific instruments for life science researchers.

036180 | KO

Overview

Corporate Details

ISIN(s):
KR7036180008
LEI:
Country:
South Korea
Address:
서울특별시 금천구 벚꽃로 244 1101호(가산동, 벽산디지털밸리5차), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GW Vitek CO., LTD. is a biotechnology company that provides comprehensive solutions and products for the life sciences research market. The company operates through two primary segments: a Bio division focused on the development, manufacturing, and sale of research antibodies, and a Scientific division that distributes a wide range of scientific instruments and laboratory equipment. Its portfolio includes products for imaging, chromatography, metabolic analysis, and general laboratory use. By collaborating with global partners, GW Vitek aims to deliver innovative and optimal solutions to support the entire research process for scientists and research institutions. The company was formerly known as A-Frontier Co Ltd.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
M&A Activity
기타경영사항(자율공시) (회생회사 지더블유바이텍 주식회사 M&A 공고)
Korean 10.7 KB
2025-09-05 00:00
Legal Proceedings Report
[기재정정]회생절차개시결정
Korean 13.0 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.5 KB
2025-08-13 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.8 MB
2025-08-06 00:00
Legal Proceedings Report
[기재정정]회생절차개시결정
Korean 12.6 KB
2025-07-04 00:00
Share Issue/Capital Change
[기재정정]감자결정(자회사의 주요경영사항)
Korean 19.2 KB
2025-06-10 00:00
Share Issue/Capital Change
감자결정(자회사의 주요경영사항)
Korean 14.6 KB
2025-06-04 00:00
Legal Proceedings Report
[기재정정]회생절차개시결정
Korean 12.2 KB
2025-05-27 00:00
Regulatory News Service
불성실공시법인지정
Korean 7.7 KB
2025-05-26 00:00
Legal Proceedings Report
[기재정정]회생절차개시결정
Korean 12.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-04-29 00:00
Regulatory News Service
불성실공시법인지정예고 (공시번복 2건)
Korean 6.3 KB
2025-04-10 00:00
Delisting Announcement
기타시장안내 (상장폐지 관련 이의신청서 접수 및 개선기간 부여)
Korean 3.9 KB
2025-04-10 00:00
Delisting Announcement
주권매매거래정지기간변경 (개선기간 부여)
Korean 5.2 KB

Automate Your Workflow. Get a real-time feed of all GW Vitek CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GW Vitek CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GW Vitek CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.